Decoy Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $749,813 | $75,532 |
| General and administrative | $1,533,926 | 1,643,163 |
| Total operating expenses | 2,283,739 | 1,718,695 |
| Loss from operations | (2,283,739) | (1,718,695) |
| Interest income and other, net | $59,111 | $9,162 |
| Loss from operations | (2,224,628) | (1,709,533) |
| Net loss | $(2,224,628) | $(1,709,533) |
| Loss from operations | (2,224,628) | (1,709,533) |
| Loss from operations attributable to common stockholders | $(2,224,628) | $(1,709,533) |
| Net loss per share attributable to common stockholders — basic and diluted | $(4.18) | $(240.07) |
| Total net loss per share | $(4.18) | $(240.07) |
| Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted | 531,968 | 7,121 |
DECOY THEREPEUTICS INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.